{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:52:20Z","timestamp":1790009540840,"version":"4.0.1"},"reference-count":218,"publisher":"Walter de Gruyter GmbH","issue":"4","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Diabetic kidney disease (DKD) is a major cause of end-stage renal disease worldwide. Its pathogenesis is highly complex and involves dysfunction across multiple renal cell types and metabolic pathways, thereby underscoring the urgent need for novel therapeutic strategies. In recent years, renal metabolic reprogramming has been increasingly recognized as a central driver of DKD progression. This review systematically examines the mechanisms of metabolic reprogramming in different renal cell types and highlights their contribution to renal injury. Particular emphasis is placed on the ability of natural products (including glycosides, terpenoids, flavonoids, alkaloids, and polysaccharides) to confer renal protection by modulating key regulatory nodes of metabolic reprogramming. Through these mechanisms, natural products enhance mitochondrial function, suppress aberrant glycolysis, and improve hypoxia-related responses. Collectively, these findings not only underscore the therapeutic potential of natural products in targeting renal metabolic reprogramming but also provide a theoretical foundation and potential molecular targets for the development of novel DKD treatment strategies.<\/jats:p>","DOI":"10.1515\/jtim-2026-0050","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T07:56:26Z","timestamp":1786521386000},"page":"524-546","source":"Crossref","is-referenced-by-count":1,"title":["Natural products modulate renal metabolic reprogramming in diabetic kidney disease"],"prefix":"10.1515","volume":"14","author":[{"given":"Wenru","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Nephrology, Xiyuan Hospital of China Academy of Chinese Medical Sciences , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Xiyuan Hospital of China Academy of Chinese Medical Sciences , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keqin","family":"Zhao","sequence":"additional","affiliation":[{"name":"Institute of Basic Theory for Chinese Medicine, China Academy of Chinese Medical Sciences , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhui","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Xiyuan Hospital of China Academy of Chinese Medical Sciences , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Xiyuan Hospital of China Academy of Chinese Medical Sciences , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianlong","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Xiyuan Hospital of China Academy of Chinese Medical Sciences , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobei","family":"Ma","sequence":"additional","affiliation":[{"name":"Institute of Basic Theory for Chinese Medicine, China Academy of Chinese Medical Sciences , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0093-3631","authenticated-orcid":false,"given":"Renhuan","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Xiyuan Hospital of China Academy of Chinese Medical Sciences , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0862-2800","authenticated-orcid":false,"given":"Peng","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Xiyuan Hospital of China Academy of Chinese Medical Sciences , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"2026082612595939129_j_jtim-2026-0050_ref_001","doi-asserted-by":"crossref","unstructured":"Wang Y, You YK, Guo J, Wang J, Shao B, et al. C-reactive protein promotes diabetic kidney disease via Smad3-mediated NLRP3 inflammasome activation. Mol Ther 2025;33:263-278.","DOI":"10.1016\/j.ymthe.2024.11.018"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_002","doi-asserted-by":"crossref","unstructured":"Liu D, Chen X, He W, Lu M, Li Q, Zhang S, et al. Update on the Pathogenesis, Diagnosis, and Treatment of Diabetic Tubulopathy. Integr Med Nephrol Androl 2024;11:e23-00029.","DOI":"10.1097\/IMNA-D-23-00029"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_003","doi-asserted-by":"crossref","unstructured":"Deng Y, Zhu H, Xing J, Gao J, Duan J, Liu P, et al. The role of natural products in improving lipid metabolism disorder-induced mitochondrial dysfunction of diabetic kidney disease. Front Physiol 2025;16:1624077.","DOI":"10.3389\/fphys.2025.1624077"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_004","doi-asserted-by":"crossref","unstructured":"Zhu W, Chen M, Wang Y, Chen Y, Zhang Y, Wang Y, et al. Regulation of renal lipid deposition in diabetic nephropathy on morroniside via inhibition of NF-KB\/TNF-\u03b1\/SREBP1c signaling pathway. Chem Biol Interact 2023;385:110711.","DOI":"10.1016\/j.cbi.2023.110711"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_005","doi-asserted-by":"crossref","unstructured":"Wang Y, Sui Z, Wang M, Liu P. Natural products in attenuating renal inflammation via inhibiting the NLRP3 inflammasome in diabetic kidney disease. Front Immunol 2023;14:1196016.","DOI":"10.3389\/fimmu.2023.1196016"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_006","doi-asserted-by":"crossref","unstructured":"Zhao H, Ma L, Yan M, Wang Y, Zhao T, Zhang H, et al. Association between MYH9 and APOL1 Gene Polymorphisms and the Risk of Diabetic Kidney Disease in Patients with Type 2 Diabetes in a Chinese Han Population. J Diabetes Res 2018;2018:5068578.","DOI":"10.1155\/2018\/5068578"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_007","doi-asserted-by":"crossref","unstructured":"Liu P, Ma L, Zhao H, Shen Z, Zhou X, Yan M, et al. Association between LXR-\u03b1 and ABCA1 Gene Polymorphisms and the Risk of Diabetic Kidney Disease in Patients with Type 2 Diabetes Mellitus in a Chinese Han Population. J Diabetes Res 2020;2020:8721536.","DOI":"10.1155\/2020\/8721536"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_008","doi-asserted-by":"crossref","unstructured":"Chen Y, Chen M, Zhu W, Zhang Y, Liu P, Li P. Morroniside attenuates podocytes lipid deposition in diabetic nephropathy: A network pharmacology, molecular docking and experimental validation study. Int Immunopharmacol 2024;138:112560.","DOI":"10.1016\/j.intimp.2024.112560"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_009","doi-asserted-by":"crossref","unstructured":"Liu P, Zhu W, Wang Y, Ma G, Zhao H, Li P. Chinese herbal medicine and its active compounds in attenuating renal injury via regulating autophagy in diabetic kidney disease. Front Endocrinol (Lausanne) 2023;14:1142805.","DOI":"10.3389\/fendo.2023.1142805"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_010","doi-asserted-by":"crossref","unstructured":"Ma L, Yan M, Kong X, Jiang Y, Zhao T, Zhao H, et al. Association of EPHX2 R287Q Polymorphism with Diabetic Nephropathy in Chinese Type 2 Diabetic Patients. J Diabetes Res 2018;2018:2786470.","DOI":"10.1155\/2018\/2786470"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_011","doi-asserted-by":"crossref","unstructured":"Ma L, Feng Z, Li P. New Insights into the Use of Traditional Chinese Medicine for Treating Diabetic Kidney Disease by Regulating DNA Methylation. Integr Med Nephrol Androl 2024;11:e24-00018.","DOI":"10.1097\/IMNA-D-24-00018"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_012","doi-asserted-by":"crossref","unstructured":"Zhao H, Zhao T, Li P. Gut Microbiota-derived Metabolites: A New Perspective of Traditional Chinese Medicine Against Diabetic Kidney Disease. Integr Med Nephrol Androl 2024;11:e23-00024.","DOI":"10.1097\/IMNA-D-23-00024"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_013","doi-asserted-by":"crossref","unstructured":"Fan X, Yang M, Lang Y, Lu S, Kong Z, Gao Y, et al. Mitochondrial metabolic reprogramming in diabetic kidney disease. Cell Death Dis 2024;15:442.","DOI":"10.1038\/s41419-024-06833-0"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_014","doi-asserted-by":"crossref","unstructured":"Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009;324:1029-1033.","DOI":"10.1126\/science.1160809"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_015","doi-asserted-by":"crossref","unstructured":"Wang W, Dai R, Cheng M, Chen Y, Gao Y, Hong X, et al. Metabolic reprogramming and renal fibrosis: what role might Chinese medicine play? Chin Med 2024;19:148.","DOI":"10.1186\/s13020-024-01004-x"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_016","doi-asserted-by":"crossref","unstructured":"Wang M, Pang Y, Guo Y, Tian L, Liu Y, Shen C, et al. Metabolic reprogramming: A novel therapeutic target in diabetic kidney disease. Front Pharmacol 2022;13:970601.","DOI":"10.3389\/fphar.2022.970601"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_017","doi-asserted-by":"crossref","unstructured":"Shiraishi T, Verdone JE, Huang J, Kahlert UD, Hernandez JR, Torga G, et al. Glycolysis is the primary bioenergetic pathway for cell motility and cytoskeletal remodeling in human prostate and breast cancer cells. Oncotarget 2015;6:130-143.","DOI":"10.18632\/oncotarget.2766"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_018","doi-asserted-by":"crossref","unstructured":"Ahmad AA, Draves SO, Rosca M. Mitochondria in diabetic kidney disease. Cells 2021;10:2945.","DOI":"10.3390\/cells10112945"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_019","doi-asserted-by":"crossref","unstructured":"Hou Y, Tan E, Shi H, Ren X, Wan X, Wu W, et al. Mitochondrial oxidative damage reprograms lipid metabolism of renal tubular epithelial cells in the diabetic kidney. Cell Mol Life Sci 2024;81:23.","DOI":"10.1007\/s00018-023-05078-y"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_020","doi-asserted-by":"crossref","unstructured":"Feng L, Gu C, Li Y, Huang J. High glucose promotes CD36 expression by upregulating peroxisome proliferator-activated receptor \u03b3 levels to exacerbate lipid deposition in renal tubular cells. Biomed Res Int 2017;2017:1414070.","DOI":"10.1155\/2017\/1414070"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_021","doi-asserted-by":"crossref","unstructured":"Chen J, Wu K, Lei Y, Huang M, Cheng L, Guan H, et al. Inhibition of Fatty Acid \u03b2-Oxidation by Fatty Acid Binding Protein 4 Induces Ferroptosis in HK2 Cells Under High Glucose Conditions. Endocrinol Metab (Seoul) 2023;38:226-244.","DOI":"10.3803\/EnM.2022.1604"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_022","doi-asserted-by":"crossref","unstructured":"Shen S, Ji C, Wei K. Cellular Senescence and Regulated Cell Death of Tubular Epithelial Cells in Diabetic Kidney Disease. Front Endocrinol (Lausanne) 2022;13:924299.","DOI":"10.3389\/fendo.2022.924299"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_023","doi-asserted-by":"crossref","unstructured":"Baek J, Sas K, He C, Nair V, Giblin W, Inoki A, et al. The deacylase sirtuin 5 reduces malonylation in nonmitochondrial metabolic pathways in diabetic kidney disease. J Biol Chem 2023;299:102960.","DOI":"10.1016\/j.jbc.2023.102960"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_024","doi-asserted-by":"crossref","unstructured":"Hallan SI, \u00d8vrehus MA, Darshi M, Montemayor D, Langlo KA, Bruheim P, et al. Metabolic Differences in Diabetic Kidney Disease Patients with Normoalbuminuria versus Moderately Increased Albuminuria. Kidney360 2023;4:1407-1418.","DOI":"10.34067\/KID.0000000000000248"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_025","doi-asserted-by":"crossref","unstructured":"Zhou X, Zhou W, Liu W, Luo M, Wu X, Wang Y, et al. A network pharmacology approach to explore the mechanism of HuangZhi YiShen Capsule for treatment of diabetic kidney disease. J Transl Int Med 2021;9:98-113.","DOI":"10.2478\/jtim-2021-0020"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_026","doi-asserted-by":"crossref","unstructured":"Han J, Wang X, Hou J, Liu Y, Liu P, Zhao T. Using Network Pharmacology to Explore the Mechanism of Peach Kernel-Safflower in the Treatment of Diabetic Nephropathy. Biomed Res Int 2021;2021:6642584.","DOI":"10.1155\/2021\/6642584"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_027","doi-asserted-by":"crossref","unstructured":"Zhong X, Jia J, Tan R, Wang L. Hederagenin Improves Adriamycin-induced Nephropathy by Inhibiting the JAK\/STAT Signaling Pathway. Integr Med Nephrol Androl 2024;11:e22-00016.","DOI":"10.1097\/IMNA-D-22-00016"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_028","doi-asserted-by":"crossref","unstructured":"Liu Y, Gao W, Wang M, Bian B, Zhou Y, Wei X, et al. The Protective Effects of Acteoside and Total Glycosides of the Leaves of Rehmannia on Three Types of Glomerular Structural Cells Under High Glucose and Inflammatory Stimulation. Integr Med Nephrol Androl 2024;11:e23-00021.","DOI":"10.1097\/IMNA-D-23-00021"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_029","doi-asserted-by":"crossref","unstructured":"Li J, Cui Y, Yao J, Guo C, Jiao M. Mechanistic insights of Rhodiola crenulata in treating diabetic kidney disease via network pharmacology. J Mol Endocrinol 2025;75:e250006.","DOI":"10.1530\/JME-25-0006"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_030","doi-asserted-by":"crossref","unstructured":"Li YX, Lu YP, Tang D, Hu B, Zhang ZY, Wu HW, et al. Anthocyanin improves kidney function in diabetic kidney disease by regulating amino acid metabolism. J Transl Med 2022;20:510.","DOI":"10.1186\/s12967-022-03717-9"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_031","doi-asserted-by":"crossref","unstructured":"Tian F, Yi X, Yang F, Chen Y, Zhu W, Liu P, et al. Research progress on the treatment of diabetic nephropathy with leech and its active ingredients. Front Endocrinol (Lausanne) 2024;15:1296843.","DOI":"10.3389\/fendo.2024.1296843"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_032","doi-asserted-by":"crossref","unstructured":"Zhou Y, Wu Q, Wang X, Li W, Liu Q, Gao K. Insights Into the Functional Mechanism of Diabetic Kidney Disease Treatment with Sinensetin Based on Network Pharmacology and Molecular Docking. Integr Med Nephrol Androl 2023;10:e00033.","DOI":"10.1097\/IMNA-D-22-00033"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_033","doi-asserted-by":"crossref","unstructured":"Wang J, Zhang R, Wu C, Wang L, Liu P, Li P. Exploring potential targets for natural product therapy of DN: the role of SUMOylation. Front Pharmacol 2024;15:1432724.","DOI":"10.3389\/fphar.2024.1432724"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_034","doi-asserted-by":"crossref","unstructured":"Li Y, Xu G. Clinical Efficacy and Safety of Jinshuibao Combined With ACEI\/ARB in the Treatment of Diabetic Kidney Disease: A Meta-Analysis of Randomized Controlled Trials. J Ren Nutr 2020;30:92-100.","DOI":"10.1053\/j.jrn.2019.03.083"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_035","doi-asserted-by":"crossref","unstructured":"Zhu Q, Zhou Q, Luo XL, Zhang XJ, Li SY. Combination of canagliflozin and puerarin alleviates the lipotoxicity to diabetic kidney in mice. Korean J Physiol Pharmacol 2023;27:221-230.","DOI":"10.4196\/kjpp.2023.27.3.221"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_036","doi-asserted-by":"crossref","unstructured":"Mohammadi S, Asghari G, Emami-Naini A, Mansourian M, Badri S. Herbal Supplement Use and Herb-drug Interactions among Patients with Kidney Disease. J Res Pharm Pract 2020;9:61-67.","DOI":"10.4103\/jrpp.JRPP_20_30"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_037","doi-asserted-by":"crossref","unstructured":"Wu Y, Cao Y, Feng L, Yan Y, Ye H, Tang K, et al. The natural compound stachyose targets SGLT2-mediated metabolic reprogramming to ameliorate diabetic kidney disease. Phytomedicine 2025;147:157182.","DOI":"10.1016\/j.phymed.2025.157182"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_038","doi-asserted-by":"crossref","unstructured":"Brinkkoetter PT, Bork T, Salou S, Liang W, Mizi A, \u00d6zel C, et al. Anaerobic Glycolysis Maintains the Glomerular Filtration Barrier Independent of Mitochondrial Metabolism and Dynamics. Cell Rep 2019;27:1551-1566.e5.","DOI":"10.1016\/j.celrep.2019.04.012"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_039","doi-asserted-by":"crossref","unstructured":"Abe Y, Sakairi T, Kajiyama H, Shrivastav S, Beeson C, Kopp JB. Bioenergetic characterization of mouse podocytes. Am J Physiol Cell Physiol 2010;299:C464-C476.","DOI":"10.1152\/ajpcell.00563.2009"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_040","doi-asserted-by":"crossref","unstructured":"Liu P, Wang C, Wang Y, Zhang H, Liu B, Qiu X. Zishen Qingre Tongluo Formula Improves Renal Fatty Acid Oxidation and Alleviated Fibrosis via the Regulation of the TGF-\u03b21\/Smad3 Signaling Pathway in Hyperuricemic Nephrology Rats. Biomed Res Int 2021;2021:2793823.","DOI":"10.1155\/2021\/2793823"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_041","doi-asserted-by":"crossref","unstructured":"Haraldsson B, Nystr\u00f6m J, Deen WM. Properties of the glomerular barrier and mechanisms of proteinuria. Physiol Rev 2008;88:451-487.","DOI":"10.1152\/physrev.00055.2006"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_042","doi-asserted-by":"crossref","unstructured":"Gujarati NA, Vasquez JM, Bogenhagen DF, Mallipattu SK. The complicated role of mitochondria in the podocyte. Am J Physiol Renal Physiol 2020;319:F955-F965.","DOI":"10.1152\/ajprenal.00393.2020"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_043","doi-asserted-by":"crossref","unstructured":"Yu B, Shen K, Li T, Li J, Meng M, Liu W, et al. Glycolytic enzyme PFKFB3 regulates sphingosine 1-phosphate receptor 1 in proangiogenic glomerular endothelial cells under diabetic condition. Am J Physiol Cell Physiol 2023;325:C1354-C1368.","DOI":"10.1152\/ajpcell.00261.2023"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_044","doi-asserted-by":"crossref","unstructured":"Curthoys NP, Moe OW. Proximal tubule function and response to acidosis. Clin J Am Soc Nephrol 2014;9:1627-1638.","DOI":"10.2215\/CJN.10391012"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_045","doi-asserted-by":"crossref","unstructured":"Fuchs MA, Wolf M. Renal proximal tubule cells: power and finesse. J Clin Invest 2023;133:e169607.","DOI":"10.1172\/JCI169607"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_046","doi-asserted-by":"crossref","unstructured":"Schaub JA, Venkatachalam MA, Weinberg JM. Proximal Tubular Oxidative Metabolism in Acute Kidney Injury and the Transition to CKD. Kidney360 2021;2:355-364.","DOI":"10.34067\/KID.0004772020"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_047","doi-asserted-by":"crossref","unstructured":"Li S, Nagothu KK, Desai V, Lee T, Branham W, Moland C, et al. Transgenic expression of proximal tubule peroxisome proliferator-activated receptor-\u03b1 in mice confers protection during acute kidney injury. Kidney Int 2009;76:1049-1062.","DOI":"10.1038\/ki.2009.330"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_048","doi-asserted-by":"crossref","unstructured":"Kang HM, Ahn SH, Choi P, Ko YA, Han SH, Chinga F, et al. Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development. Nat Med 2015;21:37-46.","DOI":"10.1038\/nm.3762"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_049","doi-asserted-by":"crossref","unstructured":"Li ZL, Li XY, Zhou Y, Wang B, Lv LL, Liu BC. Renal tubular epithelial cells response to injury in acute kidney injury. EBioMedicine 2024;107:105294.","DOI":"10.1016\/j.ebiom.2024.105294"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_050","doi-asserted-by":"crossref","unstructured":"Aparicio-Trejo OE, Aranda-Rivera AK, Osorio-Alonso H, Mart\u00ednez-Klimova E, S\u00e1nchez-Lozada LG, Pedraza-Chaverri J, et al. Extracellular Vesicles in Redox Signaling and Metabolic Regulation in Chronic Kidney Disease. Antioxidants (Basel) 2022;11:356.","DOI":"10.3390\/antiox11020356"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_051","doi-asserted-by":"crossref","unstructured":"Chen M, Chen Y, Zhu W, Yan X, Xiao J, Zhang P, et al. Advances in the pharmacological study of Chinese herbal medicine to alleviate diabetic nephropathy by improving mitochondrial oxidative stress. Biomed Pharmacother 2023;165:115088.","DOI":"10.1016\/j.biopha.2023.115088"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_052","doi-asserted-by":"crossref","unstructured":"Chang X, Zhou S, Liu J, Wang Y, Guan X, Wu Q, et al. Zishen Tongyang Huoxue decoction (TYHX) alleviates sinoatrial node cell ischemia\/reperfusion injury by directing mitochondrial quality control via the VDACC1-\u03b2-tubulin signaling axis. J Ethnopharmacol 2024;320:117371.","DOI":"10.1016\/j.jep.2023.117371"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_053","doi-asserted-by":"crossref","unstructured":"Chang X, Li Y, Liu J, Wang Y, Guan X, Wu Q, et al. \u03b2-tubulin contributes to Tongyang Huoxue decoction-induced protection against hypoxia\/reoxygenation-induced injury of sinoatrial node cells through SIRT1-mediated regulation of mitochondrial quality surveillance. Phytomedicine 2023;108:154502.","DOI":"10.1016\/j.phymed.2022.154502"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_054","doi-asserted-by":"crossref","unstructured":"Chang X, Zhang Q, Huang Y, Liu J, Wang Y, Guan X, et al. Quercetin inhibits necroptosis in cardiomyocytes after ischemia-reperfusion via DNA-PKcs-SIRT5-orchestrated mitochondrial quality control. Phytother Res 2024;38:2496-2517.","DOI":"10.1002\/ptr.8177"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_055","doi-asserted-by":"crossref","unstructured":"Atici AE, Crother TR, Noval Rivas M. Mitochondrial quality control in health and cardiovascular diseases. Front Cell Dev Biol 2023;11:1290046.","DOI":"10.3389\/fcell.2023.1290046"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_056","doi-asserted-by":"crossref","unstructured":"Zhang X, Zhang L, Xiang W. The impact of mitochondrial dysfunction on ovarian aging. J Transl Med 2025;23:211.","DOI":"10.1186\/s12967-025-06223-w"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_057","doi-asserted-by":"crossref","unstructured":"Higgins GC, Coughlan MT. Mitochondrial dysfunction and mitophagy: the beginning and end to diabetic nephropathy? Br J Pharmacol 2014;171:1917-1942.","DOI":"10.1111\/bph.12503"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_058","doi-asserted-by":"crossref","unstructured":"Mizuno M, Kuno A, Yano T, Miki T, Oshima H, Sato T, et al. Empagliflozin normalizes the size and number of mitochondria and prevents reduction in mitochondrial size after myocardial infarction in diabetic hearts. Physiol Rep 2018;6:e13741.","DOI":"10.14814\/phy2.13741"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_059","doi-asserted-by":"crossref","unstructured":"Bhargava P, Schnellmann RG. Mitochondrial energetics in the kidney. Nat Rev Nephrol 2017;13:629-646.","DOI":"10.1038\/nrneph.2017.107"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_060","doi-asserted-by":"crossref","unstructured":"Forbes JM, Thorburn DR. Mitochondrial dysfunction in diabetic kidney disease. Nat Rev Nephrol 2018;14:291-312.","DOI":"10.1038\/nrneph.2018.9"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_061","doi-asserted-by":"crossref","unstructured":"Coughlan MT, Nguyen TV, Penfold SA, Higgins GC, Thallas-Bonke V, Tan SM, et al. Mapping time-course mitochondrial adaptations in the kidney in experimental diabetes. Clin Sci (Lond) 2016;130:711-720.","DOI":"10.1042\/CS20150838"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_062","doi-asserted-by":"crossref","unstructured":"Wang W, Wang Y, Long J, Wang J, Haudek SB, Overbeek P, et al. Mitochondrial fission triggered by hyperglycemia is mediated by ROCK1 activation in podocytes and endothelial cells. Cell Metab 2012;15:186-200.","DOI":"10.1016\/j.cmet.2012.01.009"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_063","doi-asserted-by":"crossref","unstructured":"Zhan M, Usman IM, Sun L, Kanwar YS. Disruption of renal tubular mitochondrial quality control by Myo-inositol oxygenase in diabetic kidney disease. J Am Soc Nephrol 2015;26:1304-1321.","DOI":"10.1681\/ASN.2014050457"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_064","doi-asserted-by":"crossref","unstructured":"Xiao L, Zhu X, Yang S, Liu F, Zhou Z, Zhan M, et al. Rap1 ameliorates renal tubular injury in diabetic nephropathy. Diabetes 2014;63:1366-1380.","DOI":"10.2337\/db13-1412"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_065","doi-asserted-by":"crossref","unstructured":"Huang C, Zhang Y, Kelly DJ, Tan CY, Gill A, Cheng D, et al. Thioredoxin interacting protein (TXNIP) regulates tubular autophagy and mitophagy in diabetic nephropathy through the mTOR signaling pathway. Sci Rep 2016;6:29196.","DOI":"10.1038\/srep29196"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_066","doi-asserted-by":"crossref","unstructured":"Huang C, Lin MZ, Cheng D, Braet F, Pollock CA, Chen XM. Thioredoxin-interacting protein mediates dysfunction of tubular autophagy in diabetic kidneys through inhibiting autophagic flux. Lab Invest 2014;94:309-320.","DOI":"10.1038\/labinvest.2014.2"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_067","doi-asserted-by":"crossref","unstructured":"Sheng J, Li H, Dai Q, Lu C, Xu M, Zhang J, et al. NR4A1 Promotes Diabetic Nephropathy by Activating Mff-Mediated Mitochondrial Fission and Suppressing Parkin-Mediated Mitophagy. Cell Physiol Biochem 2018;48:1675-1693.","DOI":"10.1159\/000492292"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_068","doi-asserted-by":"crossref","unstructured":"Li W, Du M, Wang Q, Ma X, Wu L, Guo F, et al. FoxO1 Promotes Mitophagy in the Podocytes of Diabetic Male Mice via the PINK1\/Parkin Pathway. Endocrinology 2017;158:2155-2167.","DOI":"10.1210\/en.2016-1970"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_069","doi-asserted-by":"crossref","unstructured":"Ross BD, Espinal J, Silva P. Glucose metabolism in renal tubular function. Kidney Int 1986;29:54-67.","DOI":"10.1038\/ki.1986.8"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_070","doi-asserted-by":"crossref","unstructured":"Lee WC, Chau YY, Ng HY, Chen CH, Wang PW, Liou CW, et al. Empagliflozin Protects HK-2 Cells from High Glucose-Mediated Injuries via a Mitochondrial Mechanism. Cells 2019;8:1085.","DOI":"10.3390\/cells8091085"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_071","doi-asserted-by":"crossref","unstructured":"Li J, Liu H, Takagi S, Nitta K, Kitada M, Srivastava SP, et al. Renal protective effects of empagliflozin via inhibition of EMT and aberrant glycolysis in proximal tubules. JCI Insight 2020;5:e129034.","DOI":"10.1172\/jci.insight.129034"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_072","doi-asserted-by":"crossref","unstructured":"Zhu M, Ding Q, Lin Z, Chen X, Chen S, Zhu Y. New insights of epigenetics in vascular and cellular senescence. J Transl Int Med 2021;9:239-248.","DOI":"10.2478\/jtim-2021-0049"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_073","doi-asserted-by":"crossref","unstructured":"Preobrazenski N, Mladen SPS, Causer E, Menezes E, Islam H, Drouin PJ, et al. Mitochondrial and cardiovascular responses to aerobic exercise training in supine and upright positions in healthy young adults: a randomized parallel arm trial. Transl Exerc Biomed 2025;2:9-20.","DOI":"10.1515\/teb-2025-0002"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_074","doi-asserted-by":"crossref","unstructured":"Song X, Pickel L, Sung HK, Scholey J, Pei Y. Reprogramming of Energy Metabolism in Human PKD1 Polycystic Kidney Disease: A Systems Biology Analysis. Int J Mol Sci 2024;25:7173.","DOI":"10.3390\/ijms25137173"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_075","doi-asserted-by":"crossref","unstructured":"Qin X, Zhao Y, Gong J, Huang W, Su H, Yuan F, et al. Berberine protects glomerular podocytes via inhibiting drp1-mediated mitochondrial fission and dysfunction. Theranostics 2019;9:1698-1713.","DOI":"10.7150\/thno.30640"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_076","doi-asserted-by":"crossref","unstructured":"Kang JS, Cho NJ, Lee SW, Lee JG, Lee JH, Yi J, et al. RIPK3 causes mitochondrial dysfunction and albuminuria in diabetic podocytopathy through PGAM5-Drp1 signaling. Metabolism 2024;159:155982.","DOI":"10.1016\/j.metabol.2024.155982"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_077","doi-asserted-by":"crossref","unstructured":"Yue R, Yan Z, Zha H, Xia Y, Huang H, Li H, et al. Inhibition of Drp1-mediated mitochondrial fission by P110 ameliorates renal injury in diabetic nephropathy. Int Immunopharmacol 2025;152:114342.","DOI":"10.1016\/j.intimp.2025.114342"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_078","doi-asserted-by":"crossref","unstructured":"Kitada K, Nakano D, Ohsaki H, Hitomi H, Minamino T, Yatabe J, et al. Hyperglycemia causes cellular senescence via a SGLT2- and p21-dependent pathway in proximal tubules in the early stage of diabetic nephropathy. J Diabetes Complications 2014;28:604-611.","DOI":"10.1016\/j.jdiacomp.2014.05.010"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_079","doi-asserted-by":"crossref","unstructured":"Petermann AT, Pippin J, Durvasula R, Pichler R, Hiromura K, Monkawa T, et al. Mechanical stretch induces podocyte hypertrophy in vitro. Kidney Int 2005;67:157-166.","DOI":"10.1111\/j.1523-1755.2005.00066.x"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_080","doi-asserted-by":"crossref","unstructured":"Pan S, Li Z, Wang Y, Liang L, Liu F, Qiao Y, et al. A Comprehensive weighted gene co-expression network analysis uncovers potential targets in diabetic kidney disease. J Transl Int Med 2022;10:359-368.","DOI":"10.2478\/jtim-2022-0053"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_081","doi-asserted-by":"crossref","unstructured":"Zou Y, Liu F, Cooper ME, Chai Z. Advances in clinical research in chronic kidney disease. J Transl Int Med 2021;9:146-149.","DOI":"10.2478\/jtim-2021-0041"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_082","doi-asserted-by":"crossref","unstructured":"Laustsen C, Lips\u00f8 K, Ostergaard JA, N\u00f8rregaard R, Flyvbjerg A, Pedersen M, et al. Insufficient insulin administration to diabetic rats increases substrate utilization and maintains lactate production in the kidney. Physiol Rep 2014;2:e12233.","DOI":"10.14814\/phy2.12233"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_083","doi-asserted-by":"crossref","unstructured":"Hou Y, Wang Q, Han B, Chen Y, Qiao X, Wang L. CD36 promotes NLRP3 inflammasome activation via the mtROS pathway in renal tubular epithelial cells of diabetic kidneys. Cell Death Dis 2021;12:523.","DOI":"10.1038\/s41419-021-03813-6"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_084","doi-asserted-by":"crossref","unstructured":"Sas KM, Kayampilly P, Byun J, Nair V, Hinder LM, Hur J, et al. Tissue-specific metabolic reprogramming drives nutrient flux in diabetic complications. JCI Insight 2016;1:e86976.","DOI":"10.1172\/jci.insight.86976"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_085","doi-asserted-by":"crossref","unstructured":"An S, Yao Y, Hu H, Wu J, Li J, Li L, et al. PDHA1 hyperacetylation-mediated lactate overproduction promotes sepsis-induced acute kidney injury via Fis1 lactylation. Cell Death Dis 2023;14:457.","DOI":"10.1038\/s41419-023-05952-4"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_086","doi-asserted-by":"crossref","unstructured":"Ruan Z, Liu J, Liu W, Huang W. Qufeng Tongluo decoction may alleviate podocyte injury induced by high glucose and hydrogen peroxide by regulating autophagy. Integr Med Nephrol Androl 2024;11:e24-00023.","DOI":"10.1097\/IMNA-D-24-00023"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_087","doi-asserted-by":"crossref","unstructured":"Shen Y, Chen L, Chen J, Qin J, Wang T, Wen F. Mitochondrial damage-associated molecular patterns in chronic obstructive pulmonary disease: Pathogenetic mechanism and therapeutic target. J Transl Int Med 2023;11:330-340.","DOI":"10.2478\/jtim-2022-0019"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_088","doi-asserted-by":"crossref","unstructured":"Czajka A, Malik AN. Hyperglycemia induced damage to mitochondrial respiration in renal mesangial and tubular cells: Implications for diabetic nephropathy. Redox Biol 2016;10:100-107.","DOI":"10.1016\/j.redox.2016.09.007"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_089","doi-asserted-by":"crossref","unstructured":"Susztak K, Raff AC, Schiffer M, B\u00f6ttinger EP. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 2006;55:225-233.","DOI":"10.2337\/diabetes.55.01.06.db05-0894"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_090","doi-asserted-by":"crossref","unstructured":"Narravula S, Colgan SP. Hypoxia-inducible factor 1-mediated inhibition of peroxisome proliferator-activated receptor alpha expression during hypoxia. J Immunol 2001;166:7543-7548.","DOI":"10.4049\/jimmunol.166.12.7543"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_091","doi-asserted-by":"crossref","unstructured":"Huang D, Li T, Li X, Zhang L, Sun L, He X, et al. HIF-1-mediated suppression of acyl-CoA dehydrogenases and fatty acid oxidation is critical for cancer progression. Cell Rep 2014;8:1930-1942.","DOI":"10.1016\/j.celrep.2014.08.028"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_092","doi-asserted-by":"crossref","unstructured":"Cai T, Ke Q, Fang Y, Wen P, Chen H, Yuan Q, et al. Sodium-glucose cotransporter 2 inhibition suppresses HIF-1\u03b1-mediated metabolic switch from lipid oxidation to glycolysis in kidney tubule cells of diabetic mice. Cell Death Dis 2020;11:390.","DOI":"10.1038\/s41419-020-2544-7"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_093","doi-asserted-by":"crossref","unstructured":"Rinschen MM, Grahmmer F, Hoppe AK, Kohli P, Hagmann H, Kretz O, et al. YAP-mediated mechanotransduction determines the podocyte's response to damage. Sci Signal 2017;10:eaf8165.","DOI":"10.1126\/scisignal.aaf8165"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_094","doi-asserted-by":"crossref","unstructured":"Qi W, Keenan HA, Li Q, Ishikado A, Kannt A, Sadowski T, et al. Pyruvate kinase M2 activation may protect against the progression of diabetic glomerular pathology and mitochondrial dysfunction. Nat Med 2017;23:753-762.","DOI":"10.1038\/nm.4328"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_095","doi-asserted-by":"crossref","unstructured":"Liang J, Shi J, Song A, Lu M, Zhang K, Xu M, et al. Structures and mechanism of the human mitochondrial pyruvate carrier. Nature 2025;641:258-265.","DOI":"10.1038\/s41586-025-08873-8"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_096","doi-asserted-by":"crossref","unstructured":"Feng J, Ma Y, Chen Z, Hu J, Yang Q, Ding G. Mitochondrial pyruvate carrier 2 mediates mitochondrial dysfunction and apoptosis in high glucose-treated podocytes. Life Sci 2019;237:116941.","DOI":"10.1016\/j.lfs.2019.116941"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_097","doi-asserted-by":"crossref","unstructured":"Feng J, Feng L, Yan Y, Ye H, Tang K, Guo X, et al. SIRT3 deficiency aggravates mitochondrial metabolic disorder and podocyte injury in DKD via MPC2 acetylation. Cell Signal 2025;135:112029.","DOI":"10.1016\/j.cellsig.2025.112029"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_098","doi-asserted-by":"crossref","unstructured":"Ozawa S, Ueda S, Imamura H, Mori K, Asanuma K, Yanagita M, et al. Glycolysis, but not Mitochondria, responsible for intracellular ATP distribution in cortical area of podocytes. Sci Rep 2015;5:18575.","DOI":"10.1038\/srep18575"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_099","doi-asserted-by":"crossref","unstructured":"Wang A, Yang Y, He Y, Chen G, Ling B, Cheng X. Network pharmacological investigation and experimental verification of the peel of Zea mays L. regulating metabolic reprogramming in the treatment of diabetic nephropathy. Front Endocrinol (Lausanne) 2025;16:1594782.","DOI":"10.3389\/fendo.2025.1594782"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_100","doi-asserted-by":"crossref","unstructured":"Sugita E, Hayashi K, Hishikawa A, Itoh H. Epigenetic alterations in podocytes in diabetic nephropathy. Front Pharmacol 2021;12:759299.","DOI":"10.3389\/fphar.2021.759299"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_101","doi-asserted-by":"crossref","unstructured":"Lin X, Lei XQ, Yang JK, Jia J, Zhong X, Tan RZ, et al. Astragalus mongholicus Bunge and Panax notoginseng formula (A&P) improves renal mesangial cell damage in diabetic nephropathy by inhibiting the inflammatory response of infiltrated macrophages. BMC Complement Med Ther 2022;22:17.","DOI":"10.1186\/s12906-021-03477-x"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_102","doi-asserted-by":"crossref","unstructured":"Goruppi S, Bonventre JV, Kyriakis JM. Signaling pathways and late-onset gene induction associated with renal mesangial cell hypertrophy. EMBO J 2002;21:5427-5436.","DOI":"10.1093\/emboj\/cdf535"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_103","doi-asserted-by":"crossref","unstructured":"Fu H, Liu S, Bastacky SI, Wang X, Tian XJ, Zhou D. Diabetic kidney diseases revisited: A new perspective for a new era. Mol Metab 2019;30:250-263.","DOI":"10.1016\/j.molmet.2019.10.005"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_104","doi-asserted-by":"crossref","unstructured":"Tung CW, Hsu YC, Shih YH, Chang PJ, Lin CL. Glomerular mesangial cell and podocyte injuries in diabetic nephropathy. Nephrology (Carlton) 2018;23 Suppl 4:32-37.","DOI":"10.1111\/nep.13451"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_105","doi-asserted-by":"crossref","unstructured":"Bai Y, Chi K, Zhao D, Shen W, Liu R, Hao J, et al. Identification of functional heterogeneity of immune cells and tubular-immune cellular interplay action in diabetic kidney disease. J Transl Int Med 2024;12:395-405.","DOI":"10.2478\/jtim-2023-0130"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_106","doi-asserted-by":"crossref","unstructured":"Wang X, Yao B, Wang Y, Fan X, Wang S, Niu A, et al. Macrophage Cyclooxygenase-2 Protects Against Development of Diabetic Nephropathy. Diabetes 2017; 66: 494-504.","DOI":"10.2337\/db16-0773"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_107","doi-asserted-by":"crossref","unstructured":"Hughes CB, Mussman GM, Ray P, Bunn RC, Cornea V, Thrall KM, et al. Impact of an SGLT2-loss of function mutation on renal architecture, histology, and glucose homeostasis. Cell Tissue Res 2021;384:527-543.","DOI":"10.1007\/s00441-020-03358-8"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_108","unstructured":"Guo C, Islam R, Zhang S, Fang J. Metabolic reprogramming of macrophages and its involvement in inflammatory diseases. EXCLI J 2021;20:628-641."},{"key":"2026082612595939129_j_jtim-2026-0050_ref_109","doi-asserted-by":"crossref","unstructured":"Anders HJ, Ryu M. Renal microenvironments and macrophage phenotypes determine progression or resolution of renal inflammation and fibrosis. Kidney Int 2011;80:915-925.","DOI":"10.1038\/ki.2011.217"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_110","doi-asserted-by":"crossref","unstructured":"Han X, Wei J, Zheng R, Tu Y, Wang M, Chen L, et al. Macrophage SHP2 Deficiency Alleviates Diabetic Nephropathy via Suppression of MAPK\/NF-\u03baB-Dependent Inflammation. Diabetes 2024;73:780-796.","DOI":"10.2337\/db23-0700"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_111","doi-asserted-by":"crossref","unstructured":"Li J, Lin Q, Shao X, Li S, Zhu X, Wu J, et al. HIF1\u03b1-BNIP3-mediated mitophagy protects against renal fibrosis by decreasing ROS and inhibiting activation of the NLRP3 inflammasome. Cell Death Dis 2023;14:200.","DOI":"10.1038\/s41419-023-05587-5"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_112","doi-asserted-by":"crossref","unstructured":"Pavlovi\u0107 N, Krizanac M, Kumri\u0107 M, Vukojevi\u0107 K, Bo\u017ei\u0107 J. Mitochondrial Dysfunction: The Silent Catalyst of Kidney Disease Progression. Cells 2025;14:794.","DOI":"10.3390\/cells14110794"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_113","doi-asserted-by":"crossref","unstructured":"Romanello V, Sandri M. Mitochondrial Quality Control and Muscle Mass Maintenance. Front Physiol 2015;6:422.","DOI":"10.3389\/fphys.2015.00422"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_114","doi-asserted-by":"crossref","unstructured":"Lin DW, Yang TM, Ho C, Shih YH, Lin CL, Hsu YC. Targeting Macrophages: Therapeutic Approaches in Diabetic Kidney Disease. Int J Mol Sci 2024;25:4350.","DOI":"10.3390\/ijms25084350"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_115","doi-asserted-by":"crossref","unstructured":"Liu JL, Zhang L, Huang Y, Li XH, Liu YF, Zhang SM, et al. Epsin1-mediated exosomal sorting of Dll4 modulates the tubular-macrophage crosstalk in diabetic nephropathy. Mol Ther 2023;31:1451-1467.","DOI":"10.1016\/j.ymthe.2023.03.027"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_116","doi-asserted-by":"crossref","unstructured":"Peng QY, An Y, Jiang ZZ, Xu Y. The Role of Immune Cells in DKD: Mechanisms and Targeted Therapies. J Inflamm Res 2024;17:2103-2118.","DOI":"10.2147\/JIR.S457526"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_117","doi-asserted-by":"crossref","unstructured":"Zhu S, Jiang L, Liu X, Chen C, Luo X, Jiang S, et al. m6A demethylase Fto inhibited macrophage activation and glycolysis in diabetic nephropathy via m6A\/Npas2\/Hif-1\u03b1 axis. FASEB J 2025;39:e70332.","DOI":"10.1096\/fj.202403014R"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_118","doi-asserted-by":"crossref","unstructured":"Wang T, Liu H, Lian G, Zhang SY, Wang X, Jiang C. HIF1\u03b1-Induced Glycolysis Metabolism Is Essential to the Activation of Inflammatory Macrophages. Mediators Inflamm 2017;2017:9029327.","DOI":"10.1155\/2017\/9029327"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_119","doi-asserted-by":"crossref","unstructured":"Qiu B, Yuan P, Du X, Jin H, Du J, Huang Y. Hypoxia inducible factor-1\u03b1 is an important regulator of macrophage biology. Heliyon 2023;9:e17167.","DOI":"10.1016\/j.heliyon.2023.e17167"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_120","doi-asserted-by":"crossref","unstructured":"Yan Y, Tan RZ, Liu P, Li JC, Zhong X, Liao Y, et al. Oridonin Alleviates IRI-Induced Kidney Injury by Inhibiting Inflammatory Response of Macrophages via AKT-Related Pathways. Med Sci Monit 2020;26:e921114.","DOI":"10.12659\/MSM.921114"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_121","doi-asserted-by":"crossref","unstructured":"Roy R, Zayas J, Mohamed MF, Aboonabi A, Delgado K, Wallace J, et al. IL-10 Dysregulation Underlies Chemokine Insufficiency, Delayed Macrophage Response, and Impaired Healing in Diabetic Wounds. J Invest Dermatol 2022;142:692-704.e14.","DOI":"10.1016\/j.jid.2021.08.428"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_122","doi-asserted-by":"crossref","unstructured":"Yang Y, Wu C. Traditional Chinese Medicine in Ameliorating Diabetic Kidney Disease Via Modulating Gut Microbiota. Integrative Medicine in Nephrology and Andrology 2021;8:8.","DOI":"10.4103\/imna.imna_28_21"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_123","doi-asserted-by":"crossref","unstructured":"Wu C, Wang J, Zhang R, Zhao H, Li X, Wang L, et al. Research progress on Cornus officinalis and its active compounds in the treatment of diabetic nephropathy. Front Pharmacol 2023;14:1207777.","DOI":"10.3389\/fphar.2023.1207777"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_124","doi-asserted-by":"crossref","unstructured":"Chen H, Su X, Li Y, Dang C, Luo Z. Identification of metabolic reprogramming-related genes as potential diagnostic biomarkers for diabetic nephropathy based on bioinformatics. Diabetol Metab Syndr 2024;16:287.","DOI":"10.1186\/s13098-024-01531-5"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_125","doi-asserted-by":"crossref","unstructured":"Zhang Y, Zhu JH, Zhou Y, Li ZT, Liu H, Ma RX, et al. Activation of HIF-1\u03b1 C-terminal transactivation domain promotes tubulointerstitial fibrosis through hexokinase 2-mediated metabolic reprogramming. Cell Signal 2025;127:111531.","DOI":"10.1016\/j.cellsig.2024.111531"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_126","doi-asserted-by":"crossref","unstructured":"Zhou J. Bioactive glycosides from Chinese medicines. Mem Inst Oswaldo Cruz 1991;86 Suppl 2:231-234.","DOI":"10.1590\/S0074-02761991000600051"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_127","doi-asserted-by":"crossref","unstructured":"Ati J, Lafite P, Daniellou R. Enzymatic synthesis of glycosides: from natural O- and N-glycosides to rare C- and S-glycosides. Beilstein J Org Chem 2017;13:1857-1865.","DOI":"10.3762\/bjoc.13.180"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_128","doi-asserted-by":"crossref","unstructured":"Chen Y, Liu Y, Cao A. The potential of Huangqi decoction for treating diabetic kidney disease. Integr Med Nephrol Androl 2024;11:e00020.","DOI":"10.1097\/IMNA-D-23-00020"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_129","doi-asserted-by":"crossref","unstructured":"Liang Y, Chen B, Liang D, Quan X, Gu R, Meng Z, et al. Pharmacological Effects of Astragaloside IV: A Review. Molecules 2023;28:6118.","DOI":"10.3390\/molecules28166118"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_130","doi-asserted-by":"crossref","unstructured":"Wang J, Ke J, Wu X, Yan Y. Astragaloside prevents UV-induced keratinocyte injury by regulating TLR4\/NF-\u03baB pathway. J Cosmet Dermatol 2022;21:1163-1170.","DOI":"10.1111\/jocd.14174"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_131","doi-asserted-by":"crossref","unstructured":"Xia ML, Xie XH, Ding JH, Du RH, Hu G. Astragaloside IV inhibits astrocyte senescence: implication in Parkinson's disease. J Neuroinflammation 2020;17:105.","DOI":"10.1186\/s12974-020-01791-8"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_132","doi-asserted-by":"crossref","unstructured":"Liu Y. New insights into epithelial-mesenchymal transition in kidney fibrosis. J Am Soc Nephrol 2010;21:212-222.","DOI":"10.1681\/ASN.2008121226"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_133","doi-asserted-by":"crossref","unstructured":"Guo H, Cao A, Chu S, Wang Y, Zang Y, Mao X, et al. Astragaloside IV attenuates podocyte apoptosis mediated by endoplasmic reticulum stress through upregulating sarco\/endoplasmic reticulum Ca(2+)-ATPase 2 expression in diabetic nephropathy. Front Pharmacol 2016;7:500.","DOI":"10.3389\/fphar.2016.00500"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_134","doi-asserted-by":"crossref","unstructured":"Shen Q, Fang J, Guo H, Su X, Zhu B, Yao X, et al. Astragaloside IV attenuates podocyte apoptosis through ameliorating mitochondrial dysfunction by up-regulated Nrf2-ARE\/TFAM signaling in diabetic kidney disease. Free Radic Biol Med 2023;203:45-57.","DOI":"10.1016\/j.freeradbiomed.2023.03.022"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_135","doi-asserted-by":"crossref","unstructured":"Li L, Zou J, Zhou M, Li H, Zhou T, Liu X, et al. Phenylsulfate-induced oxidative stress and mitochondrial dysfunction in podocytes are ameliorated by Astragaloside IV activation of the SIRT1\/PGC1\u03b1\/Nrf1 signaling pathway. Biomed Pharmacother 2024;177:117008.","DOI":"10.1016\/j.biopha.2024.117008"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_136","doi-asserted-by":"crossref","unstructured":"Liu J, Yang K, Zhou L, Deng J, Rong G, Shi L, et al. A new strategy for Astragaloside IV in the treatment of diabetic kidney disease: Analyzing the regulation of ferroptosis and mitochondrial function of renal tubular epithelial cells. Int Immunopharmacol 2024;141:112794.","DOI":"10.1016\/j.intimp.2024.112794"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_137","doi-asserted-by":"crossref","unstructured":"Hao S, Huang H, Ma RY, Zeng X, Duan CY. Multifaceted functions of Drp1 in hypoxia\/ischemia-induced mitochondrial quality imbalance: from regulatory mechanism to targeted therapeutic strategy. Mil Med Res 2023;10:46.","DOI":"10.1186\/s40779-023-00482-8"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_138","doi-asserted-by":"crossref","unstructured":"Wang J, Wang L, Feng X, Xu Y, Zhou L, Wang C, et al. Astragaloside IV attenuates fatty acid-induced renal tubular injury in diabetic kidney disease by inhibiting fatty acid transport protein-2. Phytomedicine 2024;134:155991.","DOI":"10.1016\/j.phymed.2024.155991"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_139","doi-asserted-by":"crossref","unstructured":"Liu X, Wang W, Song G, Wei X, Zeng Y, Han P, et al. Astragaloside IV ameliorates diabetic nephropathy by modulating the mitochondrial quality control network. PLoS One 2017;12:e0182558.","DOI":"10.1371\/journal.pone.0182558"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_140","doi-asserted-by":"crossref","unstructured":"Ando A, Hashimoto N, Sakamoto K, Omote N, Miyazaki S, Nakahara Y, et al. Repressive role of stabilized hypoxia inducible factor 1\u03b1 expression on transforming growth factor \u03b2-induced extracellular matrix production in lung cancer cells. Cancer Sci 2019;110:1959-1973.","DOI":"10.1111\/cas.14027"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_141","doi-asserted-by":"crossref","unstructured":"Li HS, Zhou YN, Li L, Li SF, Long D, Chen XL, et al. HIF-1\u03b1 protects against oxidative stress by directly targeting mitochondria. Redox Biol 2019;25:101109.","DOI":"10.1016\/j.redox.2019.101109"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_142","doi-asserted-by":"crossref","unstructured":"Liu J, Ren J, Zhou L, Tan K, Du D, Xu L, et al. Proteomic and lipidomic analysis of the mechanism underlying astragaloside IV in mitigating ferroptosis through hypoxia-inducible factor 1\u03b1\/heme oxygenase 1 pathway in renal tubular epithelial cells in diabetic kidney disease. J Ethnopharmacol 2024;334:118517.","DOI":"10.1016\/j.jep.2024.118517"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_143","doi-asserted-by":"crossref","unstructured":"Wang H, Zhuang Z, Huang YY, Zhuang ZZ, Jin Y, Ye HY, et al. Protective effect and possible mechanisms of astragaloside IV in animal models of diabetic nephropathy: A preclinical systematic review and meta-analysis. Front Pharmacol 2020;11:988.","DOI":"10.3389\/fphar.2020.00988"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_144","doi-asserted-by":"crossref","unstructured":"Mao N, Tan RZ, Wang SQ, Wei C, Shi XL, Fan JM, et al. Ginsenoside Rg1 inhibits angiotensin II-induced podocyte autophagy via AMPK\/mTOR\/PI3K pathway. Cell Biol Int 2016;40:917-925.","DOI":"10.1002\/cbin.10634"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_145","doi-asserted-by":"crossref","unstructured":"Fan M, Lan X, Wang Q, Shan M, Fang X, Zhang Y, et al. Renal function protection and the mechanism of ginsenosides: Current progress and future perspectives. Front Pharmacol 2023;14:1070738.","DOI":"10.3389\/fphar.2023.1070738"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_146","doi-asserted-by":"crossref","unstructured":"Pu X, Zhang Q, Liu J, Wang Y, Guan X, Wu Q, et al. Ginsenoside Rb1 ameliorates heart failure through DUSP-1-TMBIM-6-mediated mitochondrial quality control and gut flora interactions. Phytomedicine 2024;132:155880.","DOI":"10.1016\/j.phymed.2024.155880"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_147","doi-asserted-by":"crossref","unstructured":"Zhang Q, Hu J, Mao A, Liu M, Guan S, Lu J. Ginsenoside Rb1 alleviated concanavalin A-induced hepatocyte pyroptosis by activating mitophagy. Food Funct 2023;14:3793-3803.","DOI":"10.1039\/D2FO03130B"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_148","doi-asserted-by":"crossref","unstructured":"Rajput SA, Shaukat A, Rajput IR, Kamboh AA, Iqbal Z, Saeed M, et al. Ginsenoside Rb1 prevents deoxynivalenol-induced immune injury via alleviating oxidative stress and apoptosis in mice. Ecotoxicol Environ Saf 2021;220:112333.","DOI":"10.1016\/j.ecoenv.2021.112333"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_149","doi-asserted-by":"crossref","unstructured":"Zhou P, Xie W, Sun Y, Dai Z, Li G, Sun G, et al. Ginsenoside Rb1 and mitochondria: A short review of the literature. Mol Cell Probes 2019;43:1-5.","DOI":"10.1016\/j.mcp.2018.12.001"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_150","doi-asserted-by":"crossref","unstructured":"Zhang X, Wang L, Guo R, Xiao J, Liu X, Dong M, et al. Ginsenoside Rb1 Ameliorates Diabetic Arterial Stiffening via AMPK Pathway. Front Pharmacol 2021;12:753881.","DOI":"10.3389\/fphar.2021.753881"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_151","doi-asserted-by":"crossref","unstructured":"He JY, Hong Q, Chen BX, Cui SY, Liu R, Cai GY, et al. Ginsenoside Rb1 alleviates diabetic kidney podocyte injury by inhibiting aldose reductase activity. Acta Pharmacol Sin 2022;43:342-353.","DOI":"10.1038\/s41401-021-00788-0"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_152","doi-asserted-by":"crossref","unstructured":"Zhang H, Liang H, Fan L, Zhu X, Ji P, Su Y, et al. Ginsenoside Rg1 attenuates T2DM-induced renal damage and fibrosis by inhibiting TRPC6-ChREBP-TXNIP signaling. J Ethnopharmacol 2025;348:119863.","DOI":"10.1016\/j.jep.2025.119863"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_153","doi-asserted-by":"crossref","unstructured":"Bai XL, Deng XL, Wu GJ, Li WJ, Jin S. Rhodiola and salidroside in the treatment of metabolic disorders. Mini Rev Med Chem 2019;19:1611-1626.","DOI":"10.2174\/1389557519666190903115424"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_154","doi-asserted-by":"crossref","unstructured":"Wojdasiewicz P, Brodacki S, Cieslicka E, Turczyn P, Poniatowski LA, Lawniczak W, et al. Salidroside: A Promising Agent in Bone Metabolism Modulation. Nutrients 2024;16:2387.","DOI":"10.3390\/nu16152387"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_155","doi-asserted-by":"crossref","unstructured":"Pei D, Tian S, Bao Y, Zhang J, Xu D, Piao M. Protective effect of salidroside on streptozotocin-induced diabetic nephropathy by inhibiting oxidative stress and inflammation in rats via the Akt\/GSK-3\u03b2 signalling pathway. Pharm Biol 2022;60:1732-1738.","DOI":"10.1080\/13880209.2022.2116055"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_156","doi-asserted-by":"crossref","unstructured":"Xue H, Li P, Luo Y, Wu C, Liu Y, Qin X, et al. Salidroside stimulates the Sirt1\/PGC-1\u03b1 axis and ameliorates diabetic nephropathy in mice. Phytomedicine 2019;54:240-247.","DOI":"10.1016\/j.phymed.2018.10.031"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_157","unstructured":"Alameddine A, Fajloun Z, Bourreau J, Gauquelin-Koch G, Yuan M, Ganguier D, et al. The cardiovascular effects of salidroside in the Goto-Kakizaki diabetic rat model. J Physiol Pharmacol 2015;66:249-57."},{"key":"2026082612595939129_j_jtim-2026-0050_ref_158","doi-asserted-by":"crossref","unstructured":"Zhang L, Wei W. Anti-inflammatory and immunoregulatory effects of paeoniflorin and total glucosides of paeony. Pharmacol Ther 2020;207:107452.","DOI":"10.1016\/j.pharmthera.2019.107452"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_159","doi-asserted-by":"crossref","unstructured":"Shao YX, Gong Q, Qi XM, Wang K, Wu YG. Paeoniflorin ameliorates macrophage infiltration and activation by inhibiting the TLR4 signaling pathway in diabetic nephropathy. Front Pharmacol 2019;10:566.","DOI":"10.3389\/fphar.2019.00566"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_160","doi-asserted-by":"crossref","unstructured":"Cao Y, Xiong J, Guan X, Yin S, Chen J, Yuan S, et al. Paeoniflorin suppresses kidney inflammation by regulating macrophage polarization via KLF4-mediated mitophagy. Phytomedicine 2023;116:154901.","DOI":"10.1016\/j.phymed.2023.154901"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_161","doi-asserted-by":"crossref","unstructured":"Li R, Xia J, Shi C, Zhang K, Qu Y, He G, et al. Direct pharmacological targeting of Piezo1 by Paeoniflorin: a novel therapeutic approach for renal fibrosis. J Adv Res 2026;82:1133-1148.","DOI":"10.1016\/j.jare.2025.07.015"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_162","doi-asserted-by":"crossref","unstructured":"Atriya A, Majee C, Mazumder R, Choudhary AN, Salahuddin, Mazumder A, et al. Insight into the various approaches for the enhancement of bio-availability and pharmacological potency of terpenoids: A review. Curr Pharm Biotechnol 2023;24:1228-1244.","DOI":"10.2174\/1389201024666221130163116"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_163","doi-asserted-by":"crossref","unstructured":"Bergman ME, Davis B, Phillips MA. Medically useful plant terpenoids: Biosynthesis, occurrence, and mechanism of action. Molecules 2019;24:3961.","DOI":"10.3390\/molecules24213961"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_164","doi-asserted-by":"crossref","unstructured":"El-Baba C, Baassiri A, Kiriako G, Dia B, Fadlallah S, Moodad S, et al. Terpenoids' anti-cancer effects: focus on autophagy. Apoptosis 2021;26:491-511.","DOI":"10.1007\/s10495-021-01684-y"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_165","doi-asserted-by":"crossref","unstructured":"Ge J, Liu Z, Zhong Z, Wang L, Zhuo X, Li J, et al. Natural terpenoids with anti-inflammatory activities: Potential leads for anti-inflammatory drug discovery. Bioorg Chem 2022;124:105817.","DOI":"10.1016\/j.bioorg.2022.105817"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_166","doi-asserted-by":"crossref","unstructured":"Roy S, Ghosh A, Majie A, Karmakar V, Das S, Dinda SC, et al. Terpenoids as potential phytoconstituent in the treatment of diabetes: From preclinical to clinical advancement. Phytomedicine 2024;129:155638.","DOI":"10.1016\/j.phymed.2024.155638"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_167","unstructured":"Schaneberg BT, Mikell JR, Bedir E, Khan IA. An improved HPLC method for quantitative determination of six triterpenes in Centella asiatica extracts and commercial products. Pharmazie 2003;58:381-384."},{"key":"2026082612595939129_j_jtim-2026-0050_ref_168","unstructured":"Chen YN, Wu CG, Shi BM, Qian K, Ding Y. The protective effect of asiatic acid on podocytes in the kidney of diabetic rats. Am J Transl Res 2018;10:3733-3741."},{"key":"2026082612595939129_j_jtim-2026-0050_ref_169","doi-asserted-by":"crossref","unstructured":"Nguyen TT, Wei S, Nguyen TH, Jo Y, Zhang Y, Park W, et al. Mitochondria-associated programmed cell death as a therapeutic target for age-related disease. Exp Mol Med 2023;55:1595-1619.","DOI":"10.1038\/s12276-023-01046-5"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_170","doi-asserted-by":"crossref","unstructured":"Wai T. Is mitochondrial morphology important for cellular physiology? Trends Endocrinol Metab 2024;35:854-871.","DOI":"10.1016\/j.tem.2024.05.005"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_171","doi-asserted-by":"crossref","unstructured":"Ji Y, Zhang X, Chen J, Song S, Fang S, Wang Z, et al. Asiatic acid attenuates tubular injury in diabetic kidney disease by regulating mitochondrial dynamics via the Nrf-2 pathway. Phytomedicine 2023;109:154552.","DOI":"10.1016\/j.phymed.2022.154552"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_172","doi-asserted-by":"crossref","unstructured":"Chen DQ, Chen L, Guo Y, Wu XQ, Zhao TT, Zhao HL, et al. Poricoic acid A suppresses renal fibroblast activation and interstitial fibrosis in UUO rats via upregulating Sirt3 and promoting \u03b2-catenin K49 deacetylation. Acta Pharmacol Sin 2023;44:1038-1050.","DOI":"10.1038\/s41401-022-01026-x"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_173","doi-asserted-by":"crossref","unstructured":"Li Q, Ming Y, Jia H, Wang G. Poricoic acid A suppresses TGF-\u03b21-induced renal fibrosis and proliferation via the PDGF-C, Smad3 and MAPK pathways. Exp Ther Med 2021;21:289.","DOI":"10.3892\/etm.2021.9720"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_174","doi-asserted-by":"crossref","unstructured":"Zhang W. The mitophagy receptor FUN14 domain-containing 1 (FUNDC1): A promising biomarker and potential therapeutic target of human diseases. Genes Dis 2021;8:640-654.","DOI":"10.1016\/j.gendis.2020.08.011"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_175","doi-asserted-by":"crossref","unstructured":"Wu Y, Deng H, Sun J, Tang J, Li X, Xu Y. Poricoic acid A induces mitophagy to ameliorate podocyte injury in diabetic kidney disease via downregulating FUNDC1. J Biochem Mol Toxicol 2023;37:e23503.","DOI":"10.1002\/jbt.23503"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_176","unstructured":"Han P, Wang Y, Zhan H, Weng W, Yu X, Ge N, et al. Artemether ameliorates type 2 diabetic kidney disease by increasing mitochondrial pyruvate carrier content in db\/db mice. Am J Transl Res 2019;11:1389-1402."},{"key":"2026082612595939129_j_jtim-2026-0050_ref_177","doi-asserted-by":"crossref","unstructured":"Upadhyay M, Agarwal S. Ironing the mitochondria: Relevance to its dynamics. Mitochondrion 2020;50:82-87.","DOI":"10.1016\/j.mito.2019.09.007"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_178","doi-asserted-by":"crossref","unstructured":"Battaglia AM, Chirillo R, Aversa I, Sacco A, Costanzo F, Biamonte F. Ferroptosis and Cancer: Mitochondria Meet the \"Iron Maiden\" Cell Death. Cells 2020;9:1505.","DOI":"10.3390\/cells9061505"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_179","doi-asserted-by":"crossref","unstructured":"Wang X, Fang X, Zheng W, Zhou J, Song Z, Xu M, et al. Genetic support of a causal relationship between iron status and type 2 diabetes: A mendelian randomization study. J Clin Endocrinol Metab 2021;106:e4641-e4651.","DOI":"10.1210\/clinem\/dgab454"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_180","doi-asserted-by":"crossref","unstructured":"Rong G, Weng W, Huang J, Chen Y, Yu X, Yuan R, et al. Artemether alleviates diabetic kidney disease by modulating amino acid metabolism. Biomed Res Int 2022;2022:7339611.","DOI":"10.1155\/2022\/7339611"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_181","doi-asserted-by":"crossref","unstructured":"Pucker B, Selmar D. Biochemistry and molecular basis of intracellular flavonoid transport in plants. Plants (Basel) 2022;11:963.","DOI":"10.3390\/plants11070963"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_182","unstructured":"Xiao J. Dietary flavonoid aglycones and their glycosides: Which show better biological significance? Crit Rev Food Sci Nutr 2017;57:1874-1905."},{"key":"2026082612595939129_j_jtim-2026-0050_ref_183","doi-asserted-by":"crossref","unstructured":"Hu Q, Qu C, Xiao X, Zhang W, Jiang Y, Wu Z, et al. Flavonoids on diabetic nephropathy: advances and therapeutic opportunities. Chin Med 2021;16:74.","DOI":"10.1186\/s13020-021-00485-4"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_184","doi-asserted-by":"crossref","unstructured":"Xu D, Hu MJ, Wang YQ, Cui YL. Antioxidant Activities of Quercetin and Its Complexes for Medicinal Application. Molecules 2019;24:1123.","DOI":"10.3390\/molecules24061123"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_185","doi-asserted-by":"crossref","unstructured":"Roy S, Ezati P, Khan A, Rhim JW. New opportunities and advances in quercetin-added functional packaging films for sustainable packaging applications: a mini-review. Crit Rev Food Sci Nutr 2024;64:8464-8479.","DOI":"10.1080\/10408398.2023.2200553"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_186","doi-asserted-by":"crossref","unstructured":"Kandeel M, Kitade Y, Almubarak A. Repurposing FDA-approved phyto-medicines, natural products, antivirals and cell protectives against SARS-CoV-2 (COVID-19) RNA-dependent RNA polymerase. PeerJ 2020;8:e10480.","DOI":"10.7717\/peerj.10480"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_187","doi-asserted-by":"crossref","unstructured":"Xu WL, Liu S, Li N, Ye LF, Zha M, Li CY, et al. Quercetin antagonizes glucose fluctuation induced renal injury by inhibiting aerobic glycolysis via HIF-1\u03b1\/miR-210\/ISCU\/FeS pathway. Front Med (Lausanne) 2021;8:656086.","DOI":"10.3389\/fmed.2021.656086"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_188","doi-asserted-by":"crossref","unstructured":"Guo Y, Bruno RS. Endogenous and exogenous mediators of quercetin bioavailability. J Nutr Biochem 2015;26:201-210.","DOI":"10.1016\/j.jnutbio.2014.10.008"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_189","doi-asserted-by":"crossref","unstructured":"Yuan Z, Meng J, Shen X, Wang M, Yu Y, Shi L, et al. Formononetin mitigates liver fibrosis via promoting hepatic stellate cell senescence and inhibiting EZH2\/YAP Axis. J Agric Food Chem 2024;72:22606-22620.","DOI":"10.1021\/acs.jafc.4c05529"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_190","doi-asserted-by":"crossref","unstructured":"Qian L, Xu H, Yuan R, Yun W, Ma Y. Formononetin ameliorates isoproterenol induced cardiac fibrosis through improving mitochondrial dysfunction. Biomed Pharmacother 2024;170:116000.","DOI":"10.1016\/j.biopha.2023.116000"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_191","doi-asserted-by":"crossref","unstructured":"Huang Q, Chen H, Yin K, Shen Y, Lin K, Guo X, et al. Formononetin attenuates renal tubular injury and mitochondrial damage in diabetic nephropathy partly via regulating Sirt1\/PGC-1\u03b1 pathway. Front Pharmacol 2022;13:901234.","DOI":"10.3389\/fphar.2022.901234"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_192","doi-asserted-by":"crossref","unstructured":"Maeda H, Dudareva N. The shikimate pathway and aromatic amino Acid biosynthesis in plants. Annu Rev Plant Biol 2012;63:73-105.","DOI":"10.1146\/annurev-arplant-042811-105439"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_193","doi-asserted-by":"crossref","unstructured":"Qiu S, Sun H, Zhang AH, Xu HY, Yan GL, Han Y, et al. Natural alkaloids: basic aspects, biological roles, and future perspectives. Chin J Nat Med 2014;12:401-406.","DOI":"10.1016\/S1875-5364(14)60063-7"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_194","doi-asserted-by":"crossref","unstructured":"Ajebl M, Khan H, Eddouks M. Natural alkaloids and diabetes mellitus: A review. Endocr Metab Immune Disord Drug Targets 2021;21:111-130.","DOI":"10.2174\/1871530320666200821124817"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_195","doi-asserted-by":"crossref","unstructured":"Yan S, Chang J, Hao X, Liu J, Tan X, Geng Z, et al. Berberine regulates short-chain fatty acid metabolism and alleviates the colitis-associated colorectal tumorigenesis through remodeling intestinal flora. Phytomedicine 2022;102:154217.","DOI":"10.1016\/j.phymed.2022.154217"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_196","doi-asserted-by":"crossref","unstructured":"Habtemariam S. Berberine pharmacology and the gut microbiota: A hidden therapeutic link. Pharmacol Res 2020;155:104722.","DOI":"10.1016\/j.phrs.2020.104722"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_197","doi-asserted-by":"crossref","unstructured":"Utami AR, Maksum IP, Deawati Y. Berberine and its study as an anti-diabetic compound. Biology (Basel) 2023;12:973.","DOI":"10.3390\/biology12070973"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_198","doi-asserted-by":"crossref","unstructured":"Gao K, Liu Y, Li K, Liu L, Cai Y, Zhang X, et al. Nrf2-mediated ferroptosis is involved in berberine-induced alleviation of diabetic kidney disease. Phytother Res 2025;39:5604-5616.","DOI":"10.1002\/ptr.8498"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_199","doi-asserted-by":"crossref","unstructured":"Yu J, Zong GN, Wu H, Zhang KQ. Podoplanin mediates the renoprotective effect of berberine on diabetic kidney disease in mice. Acta Pharmacol Sin 2019;40:1544-1554.","DOI":"10.1038\/s41401-019-0263-3"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_200","doi-asserted-by":"crossref","unstructured":"Qin X, Jiang M, Zhao Y, Gong J, Su H, Yuan F, et al. Berberine protects against diabetic kidney disease via promoting PGC-1\u03b1-regulated mitochondrial energy homeostasis. Br J Pharmacol 2020;177:3646-3661.","DOI":"10.1111\/bph.14935"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_201","doi-asserted-by":"crossref","unstructured":"Liao X, Sharma N, Kapadia F, Zhou G, Lu Y, Hong H, et al. Kr\u00fcppel-like factor 4 regulates macrophage polarization. J Clin Invest 2011;121:2736-2749.","DOI":"10.1172\/JCI45444"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_202","doi-asserted-by":"crossref","unstructured":"Ghaleb AM, Yang VW. Kr\u00fcppel-like factor 4 (KLF4): What we currently know. Gene 2017;611:27-37.","DOI":"10.1016\/j.gene.2017.02.025"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_203","doi-asserted-by":"crossref","unstructured":"Jang C, Arany Z. Mitochondria cripple without kruppel. Trends Endocrinol Metab 2015;26:587-589.","DOI":"10.1016\/j.tem.2015.08.004"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_204","doi-asserted-by":"crossref","unstructured":"Pollak NM, Hoffman M, Goldberg IJ, Drosatos K. Kruppel-like factors: Crippling and un-crippling metabolic pathways. JACC Basic Transl Sci 2018;3:132-156.","DOI":"10.1016\/j.jacbts.2017.09.001"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_205","doi-asserted-by":"crossref","unstructured":"Tung B, Xia S. Kruppel-like factor 4 (KLF4) and its regulation on mitochondrial homeostasis. J Stem Cell Res Ther 2018;8:436.","DOI":"10.4172\/2157-7633.1000436"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_206","doi-asserted-by":"crossref","unstructured":"Cai S, Zhu H, Chen L, Yu C, Su L, Chen K, et al. Berberine Inhibits KLF4 Promoter Methylation and Ferroptosis to Ameliorate Diabetic Nephropathy in Mice. Chem Res Toxicol 2024;37:1728-1737.","DOI":"10.1021\/acs.chemrestox.4c00263"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_207","doi-asserted-by":"crossref","unstructured":"Karpman D, Loos S. A link between Kruppel-like factor 4, complement activation, and kidney damage. Kidney Int 2022;102:14-16.","DOI":"10.1016\/j.kint.2022.04.014"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_208","unstructured":"Zhang X, Guan T, Yang B, Chi Z, Wan Q, Gu HF. Protective effect of berberine on high glucose and hypoxia-induced apoptosis via the modulation of HIF-1\u03b1 in renal tubular epithelial cells. Am J Transl Res 2019;11:669-682."},{"key":"2026082612595939129_j_jtim-2026-0050_ref_209","doi-asserted-by":"crossref","unstructured":"Wang J, Wu X, Chen J, Gao T, Zhang Y, Yu N. Traditional Chinese medicine polysaccharide in nano-drug delivery systems: Current progress and future perspectives. Biomed Pharmacother 2024;173:116330.","DOI":"10.1016\/j.biopha.2024.116330"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_210","doi-asserted-by":"crossref","unstructured":"Huang G, Mei X, Hu J. The antioxidant activities of natural polysaccharides. Curr Drug Targets 2017;18:1296-1300.","DOI":"10.2174\/1389450118666170123145357"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_211","doi-asserted-by":"crossref","unstructured":"Yang J, Dong H, Wang Y, Jiang Y, Zhang W, Lu Y, et al. Cordyceps cicadae polysaccharides ameliorated renal interstitial fibrosis in diabetic nephropathy rats by repressing inflammation and modulating gut microbiota dysbiosis. Int J Biol Macromol 2020;163:442-456.","DOI":"10.1016\/j.ijbiomac.2020.06.153"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_212","doi-asserted-by":"crossref","unstructured":"Jena KK, Kolapalli SP, Mehto S, Nath P, Das B, Sahoo PK, et al. TRIM16 controls assembly and degradation of protein aggregates by modulating the p62-NRF2 axis and autophagy. EMBO J 2018;37:e98358.","DOI":"10.15252\/embj.201798358"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_213","doi-asserted-by":"crossref","unstructured":"Zheng R, Xu Q, Wang Y, Zhong Y, Zhu R. Cordyceps cicadae polysaccharides attenuate diabetic nephropathy via the miR-30a-3p\/TRIM16 axis. J Diabetes Investig 2024;15:300-314.","DOI":"10.1111\/jdi.14116"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_214","doi-asserted-by":"crossref","unstructured":"Han J, Zuo Z, Shi X, Zhang Y, Peng Z, Xing Y, et al. Hirudin ameliorates diabetic nephropathy by inhibiting Gsdmd-mediated pyroptosis. Cell Biol Toxicol 2023;39:573-589.","DOI":"10.1007\/s10565-021-09622-z"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_215","doi-asserted-by":"crossref","unstructured":"Darby IA, Hewitson TD. Hypoxia in tissue repair and fibrosis. Cell Tissue Res 2016;365:553-562.","DOI":"10.1007\/s00441-016-2461-3"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_216","doi-asserted-by":"crossref","unstructured":"Pang X, Zhang Y, Shi X, Peng Z, Xing Y, et al. Hirudin reduces the expression of markers of the extracellular matrix in renal tubular epithelial cells in a rat model of diabetic kidney disease through the hypoxia-inducible factor-1\u03b1 (HIF-1\u03b1)\/vascular endothelial growth factor (VEGF) signaling pathway. Med Sci Monit 2020;26:e921894.","DOI":"10.12659\/MSM.921894"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_217","doi-asserted-by":"crossref","unstructured":"Wang M, Li Q, Wang S, Zuo L, Hai Y, Yuan S, et al. Astragaloside IV protects renal tubular epithelial cells against oxidative stress-induced injury by upregulating CPT1A-mediated HSD17B10 lysine succinylation in diabetic kidney disease. Phytother Res 2024;38:4519-4540.","DOI":"10.1002\/ptr.8298"},{"key":"2026082612595939129_j_jtim-2026-0050_ref_218","doi-asserted-by":"crossref","unstructured":"Cai S, Zhu H, Chen L, Yu C, Su L, Chen K, et al. Correction to \u201cBerberine Inhibits KLF4 Promoter Methylation and Ferroptosis to Ameliorate Diabetic Nephropathy in Mice\u201d. Chem Res Toxicol 2025;38:361.","DOI":"10.1021\/acs.chemrestox.5c00022"}],"container-title":["Journal of Translational Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jtim-2026-0050\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jtim-2026-0050\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T13:01:31Z","timestamp":1787749291000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jtim-2026-0050\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":218,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,8,26]]},"published-print":{"date-parts":[[2026,8,26]]}},"alternative-id":["10.1515\/jtim-2026-0050"],"URL":"https:\/\/doi.org\/10.1515\/jtim-2026-0050","relation":{},"ISSN":["2224-4018"],"issn-type":[{"value":"2224-4018","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,1]]}}}